桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2024-074 桂林莱茵生物科技股份有限公司 第六届监事会第三十一次会议决议公告 1 桂林莱茵生物科技股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 桂林莱茵生物科技股份有限公司（以下简称"公司"）关于召开公司第六届 监事会第三十一次会议的通知于 2024 年 11 月 7 日以短信、即时通讯工具及电子 邮件的方式发出，会议于 2024 年 11 月 11 日下午 16：00 在公司四楼会议室以通 讯方式召开。应出席会议监事 3 名，实出席会议监事 3 名，全体高管列席了会议， 会议由监事会主席李元元先生主持，会议的召开符合《公司法》和《公司章程》 的规定，会议合法有效。 二、监事会会议审议情况 经充分的讨论和审议，会议以记名投票方式表决，形成决议如下： 1、会议以 3 票同意、0 票反对、0 票弃权审议通过《关于调整 2022 年限制 性股票激励计划回购价格的议案》； 经审核，监事会认为：根据2023年年度权益分派实施情况，本次调整20 ...

Investment Rating - The investment rating for the company is maintained as "Buy" [7] Core Insights - The company experienced rapid growth in Q3 2024, benefiting from declining raw material costs and efficiency improvements, leading to enhanced profitability. Additionally, the company is making steady progress in the synthetic biology sector, which is beginning to show results and build a long-term competitive advantage [2][4] - For the first three quarters of 2024, the company achieved revenue of 1.17 billion yuan, a year-on-year increase of 31.61%, and a net profit attributable to shareholders of 102 million yuan, a year-on-year increase of 148.46%. In Q3 2024 alone, revenue reached 444 million yuan, up 17.96% year-on-year, with a net profit of 37 million yuan, reflecting a staggering year-on-year growth of 680.75% [2][3] Financial Performance Summary - The company's gross margin and net margin both improved, with a gross margin of 28.16% for the first three quarters of 2024, up 5.18 percentage points year-on-year, and a net margin of 9.06%, up 3.09 percentage points year-on-year. In Q3 2024, the gross margin was 27.44%, an increase of 6.35 percentage points year-on-year [3] - The company has successfully obtained 8 patent authorizations in the synthetic biology field, with 7 related to the RM series. Some products in the RM series are now ready for commercialization, addressing the demand for healthier high-intensity sweeteners [4] - The company maintains its previous profit forecasts, expecting revenues of 1.756 billion yuan, 2.080 billion yuan, and 2.470 billion yuan for 2024-2026, representing year-on-year growth rates of 17.6%, 18.4%, and 18.8%, respectively. The projected net profits for the same period are 180 million yuan, 256 million yuan, and 345 million yuan, with corresponding year-on-year growth rates of 117.8%, 42.3%, and 34.8% [6][8]

桂林莱茵生物科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）于2024年1月24日召 开第六届董事会第三十次会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有或自筹资金以集中竞价交易方式回购公司已发行的人民币普 通股（A股）股票，用于实施股权激励计划或员工持股计划，本次用于回购的资 金总额不低于人民币10,000万元（含）且不超过人民币20,000万元（含）。公司 于2024年6月3日实施2023年年度权益分派，并对本次回购股份的价格上限进行调 整，本次回购股份价格上限由不超过人民币8.50元/股（含）调整为不超过人民币 8.30元/股（含），具体回购股份的数量以回购期满时实际回购的股份数量为准。 回购股份的实施期限为自董事会审议通过回购股份方案之日起12个月。 证券代码：002166 证券简称：莱茵生物 公告编号：2024-072 桂林莱茵生物科技股份有限公司 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9号——回购股份》等相 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's revenue has steadily increased, achieving 1.17 billion yuan in revenue for the first three quarters of 2024, representing a 32% year-on-year growth. The net profit attributable to shareholders reached 102 million yuan, up 148% year-on-year, while the net profit excluding non-recurring items was 105 million yuan, a significant increase from a loss of 346,200 yuan in the same period last year [1] - The company has seen a gross margin increase of 6 percentage points to 27.44%, attributed to the use of lower-cost raw materials for monk fruit, alongside changes in product structure [1] - The company is focusing on capacity expansion and the development of synthetic biology business, with the sweet stevia extraction plant nearing completion and currently operating at a 50% capacity utilization rate [1] Summary by Sections Revenue and Profitability - For Q3 2024, the company reported revenue of 444 million yuan, an 18% increase year-on-year. The gross profit margin improved to 27.44%, and the net profit margin increased to 8.55% [1] - The company is expected to continue benefiting from the growth in plant extraction orders, with a forecasted revenue growth rate of 20% for 2024 [3] Capacity Expansion and Business Development - The company has completed the construction of its sweet stevia extraction plant and is actively enhancing its customized formulation services to meet market demand. The synthetic biology factory has also commenced operations, focusing on products like stevia RM and L-beta-galactosaccharide [1] - The company anticipates a gradual recovery in procurement prices for monk fruit as it enters the raw material purchasing season in Q4 [1] Earnings Forecast - The earnings per share (EPS) for 2024-2026 are adjusted to 0.22, 0.33, and 0.38 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 36, 24, and 21 times [1][3]

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2024-071 桂林莱茵生物科技股份有限公司 关于变更2024年度审计项目合伙人及签字注册会计师的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）于2024年4月9日召开 了第六届董事会第三十一次会议和第六届监事会第二十六次会议，审议通过了 《关于续聘致同会计师事务所（特殊普通合伙）为2024年度审计机构的议案》， 同意公司续聘致同会计师事务所（特殊普通合伙）（以下简称"致同所"）为公 司2024年度审计机构，该议案已于2024年5月6日经公司2023年度股东大会审议通 过。具体内容详见公司于2024年4月10日在《中国证券报》《证券时报》《上海 证券报》《证券日报》及巨潮资讯网（www.cninfo.com.cn）上刊登的《关于续 聘2024年度审计机构的公告》（公告编号：2024-024）。 1、基本信息 刘毅女士， 2006 年成为注册会计师，2004 年开始从事上市公司审计，2020 2024年10月31日，公司收 ...

Revenue and Profitability - Revenue for Q3 2024 reached ¥444,476,543.36, an increase of 17.96% year-over-year, and total revenue for the year-to-date is ¥1,169,965,060.76, up 31.61% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥36,728,643.32, a significant increase of 680.75% year-over-year, with a year-to-date net profit of ¥101,621,708.59, up 148.46%[2] - The net profit excluding non-recurring items for Q3 2024 was ¥39,165,818.22, reflecting an increase of 11,411.63% year-over-year, and the year-to-date figure is ¥104,525,118.79, up 2,789.46%[2] - Basic earnings per share for Q3 2024 were ¥0.05, a 400.00% increase year-over-year, with year-to-date earnings per share at ¥0.14, up 133.33%[2] - The company's operating revenue for the first nine months of 2024 reached ¥1,169,965,060.76, a 31.61% increase compared to ¥888,977,405.17 in the same period of 2023[7] - The plant extraction business generated operating income of CNY 1,148.47 million, reflecting a year-on-year growth of 29.21%[11] - Net profit attributable to shareholders reached CNY 101.62 million, marking a significant year-on-year increase of 148.46%[11] - The company reported a total comprehensive income of CNY 103,935,605.85, compared to CNY 73,421,891.74 in the previous year, reflecting a growth of 41.7%[20] - Earnings per share (EPS) for the period was CNY 0.14, up from CNY 0.06 in the previous year, reflecting improved profitability[20] Assets and Liabilities - Total assets as of the end of Q3 2024 were ¥4,940,440,819.53, representing a 6.81% increase from the end of the previous year[2] - Shareholders' equity attributable to the parent company was ¥3,039,897,697.20, a decrease of 2.93% compared to the end of the previous year[2] - The total liabilities rose to CNY 1,823,351,558.04, compared to CNY 1,421,120,433.26 in the previous year, marking an increase of 28.3%[20] - The total equity attributable to shareholders of the parent company decreased to CNY 3,039,897,697.20 from CNY 3,131,659,215.31, a decline of 2.9%[20] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was ¥142,736,454.08, an increase of 29.92% compared to the same period last year[2] - The company reported a significant increase in cash and cash equivalents, with a 139.17% rise in cash holdings due to increased sales collections[5] - The net cash flow from investing activities improved by 59.55%, with a net outflow of ¥147,738,563.43 compared to ¥365,269,140.15 in the previous year, primarily due to reduced external investments[8] - The net cash flow from financing activities surged by 411.24% to ¥89,353,855.25, driven by an increase in net bank loans[8] - The net increase in cash and cash equivalents was ¥85,649,220.62, a 130.32% improvement from a net decrease of ¥282,447,261.92 in the same period last year[8] - The cash inflow from operating activities reached CNY 1,521,695,626.79, an increase of 47.3% compared to CNY 1,032,920,684.97 in the previous period[22] - The cash outflow for investing activities totaled CNY 157,657,032.66, significantly reduced from CNY 384,966,235.51 in the prior period, indicating a decrease of 59.0%[22] - The cash inflow from financing activities amounted to CNY 852,656,045.00, compared to CNY 662,732,899.50, representing a growth of 28.7%[23] Research and Development - Research and development expenses increased by 35.73% to ¥47,363,853.57 from ¥34,894,502.03 year-on-year, indicating a significant investment in innovation[7] - The synthetic biology workshop commenced operations on September 20, 2024, with a total investment of approximately CNY 210 million, expected to produce over 1,000 tons of synthetic biological products annually, generating over CNY 1 billion in annual output value[14] - The company established a collaboration with Jiangnan University to create a synthetic biology technology transformation base, enhancing its research and industrialization capabilities[15] - The company aims to enhance its competitive advantage in the natural health ingredient biosynthesis field through the dual technology route of natural extraction and biosynthesis[15] Tax and Fees - The company reported a significant decrease in tax and additional fees by 51.50%, from ¥6,539,380.75 to ¥3,171,474.18, mainly due to the absence of property tax payments by overseas subsidiaries[7] - The company’s income tax expense increased by 107.37% to ¥21,727,600.37, reflecting a rise in total profit[7] - The company received CNY 66,130,272.44 in tax refunds, a decrease of 12.2% from CNY 75,374,232.68 in the previous period[22]

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2024-070 桂林莱茵生物科技股份有限公司 关于控股股东、实际控制人部分股份解除质押的公告 三、控股股东、实际控制人股份质押情况说明 1、秦本军先生未来半年内和一年内分别到期的质押股份累计数量、占其所 持股份比例、占公司总股本比例以及对应融资余额如下表所示： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会近日接到控股 股东、实际控制人秦本军先生的通知，获悉秦本军先生将其所持有的部分公司股 份办理了解除质押，具体事项如下： 二、股东股份累计质押情况 截至公告披露日，上述股东所持质押股份情况如下： | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 情况 | | 情况 | | | 股东 | 持股数 | 持股 | 本次变动 前质押股 | 本 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2024-068 1 桂林莱茵生物科技股份有限公司 | 白昱 | - | - | - | | 0 | - | 0.00% | | --- | --- | --- | --- | --- | --- | --- | --- | | 罗华阳 | - | - | - | | 0 | - | 0.00% | | 郑辉 | - | - | - | | 0 | - | 0.00% | | 姚新德 | 集中竞价 交易 | 减持计划 期间 | 6.9424 | 5,845,164 | | 资本公积金 转增、配股 | 0.80% | | | 合计 | | | 5,845,164 | | - | 0.80% | 桂林莱茵生物科技股份有限公司 关于公司部分董事、高级管理人员减持计划期限届满 暨实施结果的公告 公司董事、常务副总经理谢永富先生，董事、副总经理白昱先生，副总经理、 董事会秘书罗华阳先生，财务总监郑辉女士及原董事姚新德先生，保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内 ...

一、董事会会议召开情况 桂林莱茵生物科技股份有限公司（以下简称"公司"）关于召开第六届董事 会第三十五次会议的通知于 2024 年 9 月 27 日以短信、即时通讯工具及电子邮件 的方式发出，会议于 2024 年 9 月 30 日上午 10：00 在公司四楼会议室以现场方 式召开。本次会议应参与表决董事 6 名，实参与表决董事 6 名，公司全体监事、 高管列席了会议。会议由董事长秦本军先生主持，会议的召开符合《公司法》和 《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 经充分的讨论和审议，会议以记名投票方式表决，形成如下决议： 1、会议以 6 票同意、0 票反对、0 票弃权审议通过《关于对全资子公司上 海碧研增资的议案》； 为满足全资子公司上海碧研生物技术有限公司的经营发展需要，优化其资产 结构，加快推动公司配方应用发展战略的实施，公司拟通过债转股的方式对上海 碧研进行增资，增资金额为人民币 19,500 万元，本次增资资金将全部计入资本 公积。 桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2024-064 桂林莱茵生物科技股份有限公司 第六届董事会第三 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2024-066 桂林莱茵生物科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 具体内容详见公司刊登于《中国证券报》《证券时报》《证券日报》《上海 证券报》和巨潮资讯网（www.cninfo.com.cn）上的《关于回购公司股份方案的 公告》（公告编号：2024-003）、《关于实施2023年年度权益分派后调整回购股 份价格上限和数量的公告》（公告编号：2024-037）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9号——回购股份》等相关规定，公司应当在每个月的前三个交易日内披露截至 上月末的回购进展情况。现将公司实施股份回购的进展情况公告如下： 一、回购公司股份的进展情况 截至 2024 年 9 月 30 日，公司通过股份回购专用证券账户以集中竞价交易方 式累计回购公司股份数量为 7,992,071 股，占公司总股本的 1.08%，最高成交价 7.00 元/股，最低成交价 5.90 元/股，成交总金额为人 ...